Compare MATW & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATW | OABI |
|---|---|---|
| Founded | 1850 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 639.2M | 696.4M |
| IPO Year | 1995 | 2021 |
| Metric | MATW | OABI |
|---|---|---|
| Price | $19.29 | $4.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $31.33 | $8.33 |
| AVG Volume (30 Days) | 670.0K | ★ 1.3M |
| Earning Date | 11-19-2026 | 10-30-2026 |
| Dividend Yield | ★ 5.27% | N/A |
| EPS Growth | ★ 59.07 | 6.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,795,737,000.00 | $18,666,000.00 |
| Revenue This Year | N/A | $87.73 |
| Revenue Next Year | N/A | $25.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.42 | $1.32 |
| 52 Week High | $30.93 | $5.43 |
| Indicator | MATW | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 48.03 | 53.88 |
| Support Level | $18.58 | $4.51 |
| Resistance Level | $19.72 | $5.06 |
| Average True Range (ATR) | 0.45 | 0.32 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 73.90 | 53.08 |
Matthews International Corp is a provider of memorialization products, industrial technologies and brand solutions. The company's segments are Memorialization, Industrial Technologies and Brand Solutions. The memorialization offerings include bronze and granite memorials, caskets, and cremation-related products and equipment for cemeteries and funeral homes. Its Industrial Technologies segment designs, manufactures, services, and sells custom energy storage systems and product identification and warehouse automation solutions. The Brand Solutions segment provides brand management, pre-media, printing plates and cylinders, imaging, digital asset management, merchandising displays, and marketing and design services. The majority of revenue is generated by Memorialization.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.